<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00366041</url>
  </required_header>
  <id_info>
    <org_study_id>03F/DE01</org_study_id>
    <nct_id>NCT00366041</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries</brief_title>
  <official_title>Multicentre Clinical Study to Compare the Efficacy and the Tolerance of Cellularised LG002 With the Efficacy and Tolerance of Uncellularised LG002 in the Treatment of Severe Burn Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Genévrier</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hôpital d'Instruction des Armées de Percy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratoires Genévrier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After severe burn injury, the full-thickness burn areas are excised (in the first week) and
      then temporarily covered with allograft (cryogenic preserved cadaver skin). This first
      covering is then replaced with thin skin meshed autograft.

      In this study, either the dermal substrates cellularised LG002 or uncellularised LG002 will
      be grafted, after excision, in symmetrical areas, in replacement of the allografts. Fourteen
      to twenty one days after this first covering, the dermal substrate will be covered with thin
      skin meshed autograft.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For lesions that cannot heal spontaneously, the wound is excised until fascia. Four
      contiguous dermal substrates (uncellularised and cellularised) are randomly grafted on each
      symmetric area.

      A primary siliconized dressing will cover the wound. Secondary dressing: dressing gauze
      impregnated with physiologic serum and/or sterile dried dressing gauze, the whole is
      maintained by a (slightly compressive) tubular or elastic bandage.

      Thin skin meshed autograft will occur 14 to 21 days after dermal substrate cellularised LG002
      or uncellularised LG002 grafting (time frame necessary for the site to vascularize).

      Meshed autograft development must be identical in both symmetric areas, for one single
      patient.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    not appropriate to carry on the study
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of take of thin skin autografts 6 days after their application on dermal substrate cellularised LG002 or uncellularised LG002 (visual assessment + photography)</measure>
    <time_frame>6 days after their application on dermal substrate cellularised LG002 or uncellularised LG002</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short and medium term: Percentage of take of thin skin autografts 12 and 30 days after their application</measure>
    <time_frame>12 and 30 days after their application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term: Clinical evaluation (Vancouver scale 1, 3, 6, 12 months) and histological evaluation (3mm biopsy) to investigate the dermal-epidermal junction and the extra-cellular matrix (1 and 6 month) in order to evaluate the scar quality</measure>
    <time_frame>1, 3, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance parameter: Investigator's global judgement, post grafting infection (swabbing during each new dressing for staphylococcus aureus detection), adverse event for intolerance</measure>
    <time_frame>each application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplementary parameter: Allogenic fibroblasts survival : chimerism study with biopsy (1 and 6 months)</measure>
    <time_frame>1 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Cellularised LG002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cellularised LG002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UnCellularised LG002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UnCellularised LG002</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dermal substrate cellularised LG002 (10x10cm)</intervention_name>
    <description>application depending on burn injury surface</description>
    <arm_group_label>Cellularised LG002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dermal substrate uncellularised LG002 (10x10 cm)</intervention_name>
    <description>depending on burn injury surface</description>
    <arm_group_label>UnCellularised LG002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with severe burn injuries ≥ 40 % of TBSA (Total Body Surface Area)

          -  Thermal burn on symmetrical areas allowing grafting of 4 contiguous dermal substrates
             (cellularised LG002 or uncellularised LG002) on each area

          -  The patient himself, or his legal representative, must give his informed consent in
             writing

        Exclusion Criteria:

          -  Anterior progressive serious illness (i.e severe hepatic insufficiency,
             immunodepression induced by corticotherapy or illness (AIDS))

          -  Metabolic disease

          -  Systemic infection or local burn infection

          -  Known allergy to collagen, streptomycin, Penicillin and/or bovine origine products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine DOSQUET, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Saint Louis, Unité thérapie cellulaire et Unité INSERM 553</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel WASSERMANN, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Cochin, Service des Brûlés</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital d' Instruction des Armées de Percy, Service des Brûlés</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin, Service des Brûlés</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Berthod F, Saintigny G, Chretien F, Hayek D, Collombel C, Damour O. Optimization of thickness, pore size and mechanical properties of a biomaterial designed for deep burn coverage. Clin Mater. 1994;15(4):259-65.</citation>
    <PMID>10147169</PMID>
  </reference>
  <reference>
    <citation>Damour O, Gueugniaud PY, Berthin-Maghit M, Rousselle P, Berthod F, Sahuc F, Collombel C. A dermal substrate made of collagen--GAG--chitosan for deep burn coverage: first clinical uses. Clin Mater. 1994;15(4):273-6.</citation>
    <PMID>10147171</PMID>
  </reference>
  <reference>
    <citation>Coulomb B, Lebreton C, Dubertret L. Influence of human dermal fibroblasts on epidermalization. J Invest Dermatol. 1989 Jan;92(1):122-5.</citation>
    <PMID>2909624</PMID>
  </reference>
  <reference>
    <citation>Berthod F, Hayek D, Damour O, Collombel C. Collagen synthesis by fibroblasts cultured within a collagen sponge. Biomaterials. 1993 Aug;14(10):749-54.</citation>
    <PMID>8218724</PMID>
  </reference>
  <reference>
    <citation>Froget S, Barthelemy E, Guillot F, Soler C, Coudert MC, Benbunan M, Dosquet C. Wound healing mediator production by human dermal fibroblasts grown within a collagen-GAG matrix for skin repair in humans. Eur Cytokine Netw. 2003 Jan-Mar;14(1):60-4.</citation>
    <PMID>12799215</PMID>
  </reference>
  <reference>
    <citation>Saintigny G, Bonnard M, Damour O, Collombel C. Reconstruction of epidermis on a chitosan cross-linked collagen-GAG lattice: effect of fibroblasts. Acta Derm Venereol. 1993 Jun;73(3):175-80.</citation>
    <PMID>8105612</PMID>
  </reference>
  <reference>
    <citation>Sher SE, Hull BE, Rosen S, Church D, Friedman L, Bell E. Acceptance of allogeneic fibroblasts in skin equivalent transplants. Transplantation. 1983 Nov;36(5):552-7.</citation>
    <PMID>6356519</PMID>
  </reference>
  <reference>
    <citation>Braye FM, Stefani A, Venet E, Pieptu D, Tissot E, Damour O. Grafting of large pieces of human reconstructed skin in a porcine model. Br J Plast Surg. 2001 Sep;54(6):532-8.</citation>
    <PMID>11513518</PMID>
  </reference>
  <reference>
    <citation>Coulomb B, Friteau L, Baruch J, Guilbaud J, Chretien-Marquet B, Glicenstein J, Lebreton-Decoster C, Bell E, Dubertret L. Advantage of the presence of living dermal fibroblasts within in vitro reconstructed skin for grafting in humans. Plast Reconstr Surg. 1998 Jun;101(7):1891-903.</citation>
    <PMID>9623833</PMID>
  </reference>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2006</study_first_submitted>
  <study_first_submitted_qc>August 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2006</study_first_posted>
  <last_update_submitted>January 20, 2010</last_update_submitted>
  <last_update_submitted_qc>January 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Laboratoires Genévrier</name_title>
    <organization>sponsor</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

